Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer
Angelika Tölle(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Silke Rabenhorst(Charité - Universitätsmedizin Berlin), Klaus Jung(University of Veterinary Medicine Hannover, Foundation), Ergin Kilic(Istanbul Technical University), Monika Jung(Charité - Universitätsmedizin Berlin)
Cited by 86
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
|International Journal of Cancer|2009|613
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218
The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
|European Journal of Cancer|2010|187
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas
|International Journal of Molecular Medicine|2005|151